Photo of Bruce T. Liang, M.D., FACC

Bruce T. Liang, M.D., FACC

Interim Chief Executive Officer, UConn Health
Executive Vice President for Health Affairs
Dean, UConn School of Medicine
Director, Pat and Jim Calhoun Cardiology Center
Ray Neag Distinguished Professor of Cardiovascular Biology and Medicine
NPI Number:
Academic Office Location:
UConn Health
263 Farmington Avenue
Farmington, CT 06030-3946
Phone: 860-679-3343

UConn School of Medicine

Calhoun Cardiology Center

Cell Biology Graduate Program

Interim CEO of UConn Health, Bruce T. Liang, M.D., is an internationally recognized cardiovascular physician-scientist and national leader in academic medicine. He is dean of UConn School of Medicine and the Ray Neag Distinguished Professor of Cardiovascular Biology and Medicine.

Dr. Liang first joined UConn Health in 2002 as a physician-scientist faculty member and was appointed dean of the medical school in 2015. As dean he has led to new heights UConn’s advancement of medicine, medical education, and research.

In 2021 Dr. Liang led the School of Medicine’s 50th anniversary celebration of its generational community impact of producing five decades of new physicians, surgeons, scientists, and community leaders to serve the state of Connecticut and beyond while increasing diversity and health equity in academic medicine. In fact, U.S. News & World Report has named it as one of the 10 most diverse medical schools in the nation, as 23% of its student body are from underrepresented groups in medicine.

Importantly, UConn Health is Connecticut’s number one producer of physicians, dentists, and surgeons, as well as a significant source of new scientists. Plus, it annually trains more than 100 postdoctoral fellows and 100 Ph.D. students. It is has one of the largest Master of Public Health programs, graduating more than 1,000 students so far with MPH degrees.

Under Dr. Liang’s leadership the medical school has received record-breaking research grant funding of over $100 million year after year. He also has overseen the school’s successful implementation of a new-age, team-based and patient-centered four-year curriculum since 2016, better preparing future physicians for the rapidly evolving health care field. In fact, UConn was the first medical school in the nation to eliminate lectures and continues to offer early, hands-on clinical care exposure at the very start of medical school along with the integration of basic sciences education. The school also has completed several successful LCME accreditation surveys under Dr. Liang’s leadership, plus it is highly ranked nationally among all other public medical schools as No. 30 in primary care and No. 31 in research by U.S. News & World Report.

As an active researcher, Dr. Liang’s cutting-edge translational research contributions have advanced scientific knowledge about heart disease. His research has been continuously funded since 1986 by the NIH, the American Heart Association, and the U.S. Department of Defense. He is widely published in the areas of cardiac myocyte, intact heart biology, and heart failure translational research. His latest research investigations have developed a new potential medication for advanced heart failure patients. This research, jointly performed with scientists at the NIH, has received patents from the U.S. and EU.

Dr. Liang is a fellow of the American Association for the Advancement of Science (AAAS), American College of Cardiology, and the American Heart Association, and is an elected member of the American Society for Clinical Investigation, the Association of University Cardiologists, the Council on Clinical Cardiology and Basic Cardiovascular Sciences, and the Connecticut Academy of Science and Engineering. He has been consistently named one of America’s Top Doctors and Best Doctors in America for cardiovascular disease care.

Prior to joining UConn Health in 2002, for 13 years he served the University of Pennsylvania School of Medicine as associate professor of medicine and pharmacology. Dr. Liang received his bachelor’s degree from Harvard in biochemistry and molecular biology and his medical degree from Harvard Medical College. He completed his internal medicine internship and residency training at the Hospital of the University of Pennsylvania and cardiology fellowship training at Brigham and Women’s Hospital and Harvard Medical School.

B.A.Harvard CollegeBiochemistry and Molecular Biology
M.D.Harvard Medical SchoolMedicine

Post-Graduate Training
InternshipHospital of the University of PennsylvaniaMedicine
ResidencyHospital of the University of PennsylvaniaInternal Medicine
FellowshipBrigham and Women's HospitalMedicine (Research/Clinical)
FellowshipHarvard Medical SchoolMedicine (Research)

Name of Award/HonorAwarding Organization
Blue Precision Designation in CardiologyAnthem Blue Cross and Blue Shield
Elected as a Member of the Connecticut Academy of Science and EngineeringConnecticut Academy of Science and Engineering
National Steering Committee of LEADERS in Clinical Weight Management
Development of a New Method to Detect Heart Failure via a Simple Blood Test
Lifetime Member of Global Who's Who
Named an America’s Top Doctor by Castle Connolly in Cardiovascular Disease Since 2006Castle Connolly Medical Ltd.
Elected and Inducted into the Association of University CardiologistsAssociation of University Cardiologists
Elected and Inducted into the American Society for Clinical InvestigationAmerican Society for Clinical Investigation
Established Investigatorship, 1993-1998 American Heart Association
First Place, Mead Johnson Excellence of Research Award National Student Research Forum
First Place, Roche Laboratories Award in Basic Sciences, National Student Research ForumRoche Laboratories
Name & DescriptionCategoryRoleTypeScopeStart YearEnd Year
Election as a new member of the Connecticut Academy of Science and EngineeringProfessional/Scientific OrganizationMemberExternalState2009
National Institute of Biomedical Imaging and Bioengineering REVIEW PANEL: Enabling Technologies for Tissue Engineering and Regenerative MedicineAdvisory CommitteePanel memberExternalNational20082009
Peer Review Committee, Integrated Cardiac Biology, Northeast Affiliate of American Heart AssocationProfessional/Scientific OrganizationCommittee MemberExternalNational2007
Association of University CardiologistsProfessional/Scientific OrganizationMemberExternalNational2005
NHLBI/NIH SCCOR Review PanelAdvisory CommitteePanel memberExternalNational2004
Center for Scientific Review, Cardiovascular System and Pharmacology ZRG1 HP Panel Professional/Scientific OrganizationPanel memberExternalNational2003
Peer Review Committee, Cardiovascular Pathophysiology III, National American Heart AssociationProfessional/Scientific OrganizationCommittee MemberExternalNational20022004
American Journal of PhysiologyEditorial BoardEditorial BoardExternalNational1999
Peer Review Committee, Molecular Signaling, National American Heart AssociationProfessional/Scientific OrganizationCommittee MemberExternalNational19972001

Dr. Liang’s research program has focused on the fundamental signaling mechanisms that regulate cardiovascular functions. Using the concepts and tools of biochemistry and molecular biology, integrated with a cellular and pharmacological approach, the program has addressed and elucidated novel functions and signaling mechanisms for the various purinergic receptors in the heart. Two tracks of development have evolved new directions and models relevant to advances in cardiovascular research. The first direction is exemplified by the development of a novel cardiac cell model for cardioprotection and ischemic preconditioning. The development of efficient cardiac myocyte transfection enables the use of an approach to delineate mechanism and to develop new receptor ligands important in protecting the myocyte against ischemia. This model is now widely recognized and is currently used by different laboratories. Certain basic observations, for example, those related to his studies on the cardiac adenosine A3 receptor, have been repeated and investigated further by others. His research has yielded new insights on the fundamental mechanisms of cardiac myocyte protection. In a second example, a new transgenic mouse line overexpressing a novel P2X purinergic ligand-gated receptor channel shows enhanced basal cardiac contractility and relaxation. This transgenic line provides the proof of principle that this ligand-gated channel is a potential novel therapeutic target for the treatment of heart failure. It is anticipated that the program will continue to develop new translational/clinical research projects. Some examples of such research include the ongoing studies on novel purine receptors and their ligands in protecting the ischemic myocardium and in treating heart failure. Study on identifying novel mutations of the adenosine transporter represents another example. Overall, He has had continuous NIH support for the last 16 years. His work advances novel concepts on signaling mechanisms and receptor function. He is an internationally recognized expert on adenosine receptor biology and myocyte function.

Not accepting students for Lab Rotations at this time

Journal Articles

Book Chapters


Conference Papers

  • PAS-Code: iOS App with Mobile Access to the International Classified Disease and Drug Databases for Health Informatics & Precision Medicine (In Press)
    Ahmed, Zeeshan; Zeeshan, Saman; Liang, Bruce T. Session: Health Informatics and Data Science, The IEEE International Conference on Bioinformatics and Biomedicine (IEEE-BIBM) 2019 Nov;13.8.
  • PAS-SNP: iOS App with GWAS SNP-Disease Database for Personalized Genomics Research (In Press)
    Ahmed, Zeeshan; Zeeshan, Saman; Liang, Bruce T. Session: Data Mining from Genomic Variants and Its Application to Genome-wide Analysis. The IEEE International Conference on Bioinformatics and Biomedicine (IEEE-BIBM). 2019 Nov;13.8.
  • Purine receptors: GPCR structure and agonist design.
    Jacobson, Kenneth A; Kim, Soo-Kyung; Costanzi, Stefano; Gao, Zhan-Guo Molecular interventions 2004 Dec;4(6):337-47